Physician

Suzanne Partridge, MD

According to 2025 Medicare claims, Suzanne Partridge, MD (NPI: 1629297932) practices hematology/oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Hamilton, OH. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY CARE INC (NPI: 1790778041; TIN: 311106418) and primary practice location at 45211-1108. Partridge is affiliated with the Mercy Health Select, LLC (ACO ID: A1215) and Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Partridge's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 569 traditional Medicare patients, billed 101,235 HCPCS/CPT codes, and received $1,878,321 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,888 prescription claims across 448 beneficiaries totaling $3,562,856 in drug costs, led by Ibrance (Palbociclib). DME data shows 23 claims. Open Payments data shows 12 records totaling $18,397. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $3,078 to $1,700.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	759	131,904	$1,253,628
2016	888	172,161	$1,710,546
2017	892	148,785	$2,136,381
2018	869	186,080	$2,904,657
2019	829	181,246	$2,872,273
2020	746	181,984	$2,857,380
2021	699	132,433	$2,239,239
2022	680	135,692	$2,156,779
2023	605	96,401	$1,657,054
2024	569	101,235	$1,878,321

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	331	2,330	$2,172,064
2016	386	2,876	$2,957,697
2017	394	2,935	$3,534,603
2018	382	2,932	$3,400,839
2019	428	2,867	$3,521,982
2020	402	2,994	$2,734,195
2021	408	2,978	$2,981,089
2022	425	2,770	$3,087,188
2023	436	2,886	$3,310,390
2024	448	2,888	$3,562,856

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	52	$33,083
2016	N/R	241	$30,378
2017	N/R	287	$17,440
2018	N/R	219	$11,769
2019	N/R	207	$3,838
2020	N/R	142	$4,961
2021	N/R	75	$5,097
2022	N/R	66	$2,791
2023	N/R	23	$3,760
2024	N/R	23	$632

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	179	505	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	348	592	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	343	748	$11
80053	Blood test, comprehensive group of blood chemicals	151	538	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	237	824	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	27	756	$433,904
Kisqali	Ribociclib Succinate	29	812	$400,345
Lenalidomide	Lenalidomide	23	644	$328,303
Lenvima	Lenvatinib Mesylate	13	390	$301,163
Revlimid	Lenalidomide	16	448	$280,546

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$494
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$147	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$18,250	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Suzanne Partridge, MD?

Tedicare shows public-source Medicare data for Suzanne Partridge, MD (NPI 1629297932), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Suzanne Partridge, MD have ACO affiliation data?

Suzanne Partridge, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215) and Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Suzanne Partridge, MD?

Suzanne Partridge, MD is linked to ONCOLOGY HEMATOLOGY CARE INC (billing NPI 1790778041) in the available physician profile data.

Does Suzanne Partridge, MD have Open Payments data?

Suzanne Partridge, MD has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.